Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. reports the results of the Annual General Meeting of Shareholders held on April 23, 2026. The meeting addressed corporate governance matters, including the approval of statutory accounts for the fiscal year ended December 31, 2025, and the re-appointment of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document confirms only that shareholders approved the adoption of the Dutch statutory annual accounts for the financial year ended December 31, 2025, without detailing the figures contained therein.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document focuses exclusively on the outcomes of shareholder votes regarding corporate governance and administrative authorizations.
Guidance, Outlook, and Governance Actions
Shareholders approved the following key agenda items:
- Audit: Instruction to KPMG Accountants N.V. to audit the 2026 statutory annual accounts.
- Liability Release: Release from liability for directors regarding their performance during the 2025 financial year.
- Director Re-appointments: Re-appointment of Executive Directors Niels Riedemann and Renfeng Guo, and Non-Executive Directors Nicolas Fulpius, Richard Brudnick, and Hege Hellstrom.
- Capital Authorization: Extension of Board authorization to issue shares, grant subscription rights, limit pre-emption rights, and acquire shares/depository receipts.
- Corporate Structure: Approval of an amendment to the Articles of Association.
- Compensation: Approval of a new Long-Term Incentive Plan (LTIP 2026).
The filing contains no specific management commentary on future outlook, risks, or contingencies beyond the standard governance approvals.
Investor Verification Checklist
- Verify the specific financial figures in the Dutch statutory annual accounts for the year ended December 31, 2025, which were approved but not detailed in this filing.
- Review the terms of the new LTIP 2026 to understand potential dilution or compensation costs.
- Examine the Deed of Amendment to the Articles of Association (Exhibit 99.1) for specific changes to corporate bylaws.
- Confirm the scope of the Board's new authorization to issue shares and limit pre-emption rights.